omiics is the company partner on multiple larger project applications

Current Partnerships:

2020: 

PRIME: omiics joined the ERC FET Open grant- EU PRIME, providing high-quality end-to-end RNAseq (Illumina technology), mainly focused on small RNA sequencing and analysis of novel tRNA fragment.

BIOMETSCO: omiics became the industry R&D partner in this ODIN project based at Aarhus Universtiy, developing novel data-analyse strategy of digital spatial profiling (DSP) data from the nCounter NanoString.

MICO Platform: omiics became the industry R&D partner in this ODIN project based at Aarhus Universtiy, establishing a single-cell (10X Genomics) analysis pipeline for organiod extracted neurons aimed at development of an in vitro model for biomarker testing and validation. 

2019: 

Innobooster: omiics was awarded a grant from the Innovation Foundation for the development of our interactive NGS software application.

Previous Partnerships:

CircRTrain consortium: omiics co-founder and CTO Morten Tillingsgaard Venø was a named partner in this  Marie Curie Innovative Training Network (ITN) funded by the European Union within the H2020 Programme. (2017-2021)

RNA-NEURO: both omiicsco-founders, Yan Yan and Morten Tillingsgaard Venø, were named partners in this JPND (Joint Program in Neurodegeneration Research) cross-Disease Analysis Consortium. RNA-NEURO aimed to provide the fingerprint of small non-coding RNA in ALS, PD and FTD in both animal models and patient samples (serum/plasma) through RNA sequencing and modification analysis. (2017-2020)

EpiMiRNA: omiics co-founder and CTO Morten Tillingsgaard Venø was the named postdoc for this collaborative EU consortia project which investigated miRNA dysregulation in epilepsy. (2013-2018)

We are currently the named company partner on multiple larger project applications for commercial products with roots in RNA sequencing technology at the Innovation Foundation, European Research Council, and ODIN via Novo Nordisk.